Chapter 22. Promoter Optimization and Artificial Promoters for Transcriptional Targeting in Gene Therapy

  1. David T. Curiel M.D. and
  2. Joanne T. Douglas Ph.D.
  1. Dirk M. Nettelbeck Ph.D.1,
  2. David T. Curiel3 and
  3. Rolf Müller Ph.D.2

Published Online: 31 MAR 2003

DOI: 10.1002/0471234303.ch22

Vector Targeting for Therapeutic Gene Delivery

Vector Targeting for Therapeutic Gene Delivery

How to Cite

Nettelbeck, D. M., Curiel, D. T. and Müller, R. (2002) Promoter Optimization and Artificial Promoters for Transcriptional Targeting in Gene Therapy, in Vector Targeting for Therapeutic Gene Delivery (eds D. T. Curiel and J. T. Douglas), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/0471234303.ch22

Editor Information

  1. Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, The University of Alabama at Birmingham, USA

Author Information

  1. 1

    Division of Human Gene Therapy and Gene Therapy Center, University of Alabama at Birmingham, Birmingham, Alabama, USA

  2. 2

    Institute of Molecular Biology and Tumor Research, Philipps-University, Marburg, Germany

  3. 3

    Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, The University of Alabama at Birmingham, USA

Publication History

  1. Published Online: 31 MAR 2003
  2. Published Print: 9 AUG 2002

ISBN Information

Print ISBN: 9780471434795

Online ISBN: 9780471234302

SEARCH

Keywords:

  • transcriptional targeting;
  • promoter optimization;
  • artificial promoter;
  • enhancer;
  • DNA element;
  • transcription factor;
  • vector compatibility;
  • gene therapy;
  • gene transfer vector;
  • viral oncolysis

Summary

Transcriptional targeting facilitates spatial, inducible or physiologically regulated gene therapy or virotherapy by the utilization of regulatory DNA sequences to drive expression of therapeutic or viral genes. Specific, effective, and vector-compatible promoters are key to the realization of the full potential of transcriptional targeting. Few promoters that fulfill these requirements have been described and for some applications suitable natural promoters might not exist. This chapter reviews strategies developed to overcome these limitations: optimization of natural promoters, design of artificial promoters, and adaptation of vector backbones. These endeavors aim to develop advanced vectors required for future clinical applications.